Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Wednesday 1 July we are hosting an AIMday in the Microbiome, bringing academic and clinical excellence from across the University of Oxford together with industry to help answer the most pressing challenges in this area, as identified by industry.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for our virtual AIMday in the Microbiome

This event will bring together industry with academia to discuss key challenges in the microbiome sector. The AIMday format allows industry to propose challenges for one-hour roundtable discussions with groups of relevant academics and clinicians from Oxford. For academics, this is a great chance to see how your research can be applied in industry and to meet potential future collaborators. To see the list of challenges put forward by industry please click here. For more information on the event format see ‘How AIMdays work’.

This AIMday is only open to academics and clinicians affiliated with the University of Oxford/Oxford University Hospitals.

FREE registration closes on Wednesday 24 June (advance registration is essential)

Full details and to register: https://aimday.se/microbiome-oxford-2020

Similar stories

Potential for radiotherapy and VTP multimodality therapy for prostate cancer

A recent collaborative study from the University of Oxford has investigated the potential benefit of a combined therapy approach to prostate cancer treatment, using radiotherapy and vascular targeted photodynamic therapy (VTP), which could lead to first-in-man early phase clinical trials.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Oxford University and partners win government funding to evaluate Paige Prostate Cancer Detection System

A prostate cancer detection software system to help pathologists quickly identify suspicious areas of tissue, developed by Paige, will be investigated in a multicentre clinical study led by Oxford University as part of a successful NHSx Artificial Intelligence Health and Care Award application.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.